Introduction The global pandemic of coronavirus disease 2019 (COVID‐19) is caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It seems that there is an …

Background Data on the efficacy and safety of COVID-19 vaccines in patients with
malignancy are immature. In this paper, we assessed the literature involving the use of …

Simple Summary Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a tumor-
associated antigen reported to be overexpressed in a variety of malignancies. The aim of …

The rapid spread of the SARS-Cov-2 virus, the increase in the number of patients with
severe COVID-19, and the high mortality rate created the basis for the production of safe and …

Abstract Coronavirus disease 2019 (COVID-19) results in higher risks of hospitalization or
death in older patients and those with multiple comorbidities, including malignancies …

Abstract Background Since SARS‐CoV2 vaccines were approved without enough long‐term
monitoring due to emergent situations, some issues have been raised about timing and …

Background: The new severe acute respiratory syndrome coronavirus 2 has emerged as a
global pandemic that threatens thousands around the world. Observational cohort studies …

Alteration of the immune status leading to impaired immune responses is associated with a
more severe course of infectious diseases, including COVID-19. Cancer patients often …

A global threat to public health began in late 2019 with the onset of the COVID-19 pandemic
from the SARS-CoV-2 virus. In January 2022, 373,229,380 cases were reported worldwide …

Взаимодействие врожденного и адаптивного иммунитета необходимо для реализации
иммунного ответа на SARS-CoV-2. Врожденный иммунитет служит первой линией …